drugset / Trial / NCT00980083

GLP-1 - Regulatory Mechanism of Postprandial Glycemia

NCT00980083

Phase 1 Completed 12 enrolled Ludwig-Maximilians - University of Munich
RandomizedCrossoverDouble-blindBasic science

Summary

Synthetic GLP-1 lowers postprandial (pp) glycemia by stimulating insulin, inhibiting glucagon, and delaying gastric emptying. However, the effects of the endogenous peptide are largely unknown. Using the specific GLP-1 receptor antagonist exendin(9-39)amide (Ex(9-39)) the investigators recently showed that GLP-1 released during intestinal meal perfusion acts as an incretin hormone and as an enterogastrone. As the relative contributions of these effects to controll postprandial glycemia are unclear, the investigators used Ex(9-39) to investigate the mechanisms of action of GLP-1 after an oral meal in humans.

Timeline

Start
2004-10
Primary completion
2005-07
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Avexitide Peptide 900 unknown Intravenous

Indications

No indication recorded.